Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Tegilidine
- Development stage
- Phase 4
- Lead developer
- Hengrui Therapeutics
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
Tegilidine (艾苏特, Fumasuan Taijiliding) is China's first independently developed Class 1 innovative drug, a biased μ-opioid receptor agonist. Developed by Jiangsu Hengrui Medicine Co., Ltd., it was approved in China in 2024 for the treatment of moderate to severe postoperative pain, including pain after abdominal and orthopedic surgeries. Its mechanism involves preferentially activating the G-protein pathway of the μ-opioid receptor, aiming to provide effective analgesia with a potentially improved safety profile compared to traditional μ-opioid receptor agonists by reducing activation of the β-arrestin2 signaling pathway, which is associated with common opioid side effects.
- Brand names
- 艾苏特
- Other names
- 富马酸泰吉利定Fumasuan Taijiliding
Beyond the preview
Go deeper on Tegilidine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Tegilidine.